Interestingly, ruxolitinib causes decreased phosphorylation of pSTAT3Y705 in chronic ibrutinib-resistant CLL and DLBCL cells, resulting in BCL-2 downregulation and sensitization to venetoclax-induced apoptosis (Kapoor, I et al., unpublished). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.